https://www.selleckchem.com/products/kynurenic-acid.html 35, 95% CI=1.04-1.74), there was no significant association for anxiety without depression symptoms (HR=1.00, 95% CI=0.71-1.41). High anxiety assessed with diagnostic codes or by examining latent classes was, however, associated with a higher risk of heart disease. CONCLUSIONS The association between anxiety and incident heart disease may be accounted for by comorbid depression, particularly when anxiety and depression symptoms are assessed using self-report questionnaires. Differing methods of assessment and analysis, and adjustment for comorbid depression, may explain differences in findings across different studies on anxiety and the risk of heart disease.OBJECTIVE To determine the risk of suicide following the use of a 5α-reductase inhibitor, an antiandrogenic medication commonly used in the treatment of lower urinary tract symptoms using a large nationwide cohort. METHODS A retrospective population-based cohort study was performed using the Korean National Health Insurance Serviced database. The study consisted of 51,466 men aged 60 years or older who underwent health examinations between 2005 and 2006. Individuals using 5α-reductase inhibitor were compared with non-users based on drug exposure between 2003 and 2006. Individuals using a 5α-reductase inhibitor were additionally divided into tertiles based on cumulative 5α-reductase inhibitor exposure. The incidence of completed suicide was documented during 7 years of follow-up, starting January 1, 2007. RESULTS No significant risk of suicide was observed among 5α-reductase inhibitor users compared to 5α-reductase inhibitor non-users (Hazard ratio 1.02; 95% confidence interval (CI) = 0.70-1.48). Cumulative 5α-reductase inhibitor exposure was also not associated with increased risk of suicide (p for trend 0.543). CONCLUSIONS 5α-reductase inhibitor use was not associated with an elevated risk of suicide during a long-term follow-up period. A limitation of th